Document Detail


Valproic acid management of acute alcohol withdrawal.
MedLine Citation:
PMID:  16507623     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review the clinical evidence to determine the efficacy and safety of valproic acid in the management of alcohol withdrawal syndrome (AWS). DATA SOURCES: MEDLINE (1966-February 2006), EMBASE (1980-February 2006), and PubMed (1966-February 2006) searches identified pertinent studies that were conducted in humans and published in English. Key words used for identification of articles included valproic acid, ethanol, alcohol, alcoholism, alcohol withdrawal delirium, alcohol withdrawal seizures, and substance withdrawal syndrome. References of identified articles were manually searched. STUDY SELECTION AND DATA EXTRACTION: All controlled clinical trials that evaluated the use of valproic acid for the management of AWS in humans were included. DATA SYNTHESIS: Comparisons were made among various regimens of valproic acid and traditional therapy with benzodiazepine or nonbenzodiazepine agents. Only 2 of 6 trials reported a statistically significant difference in favor of valproic acid on endpoints of AWS. However, these differences were of marginal clinical significance. The number of patients included in these studies did not allow for adequate evaluation of safety. CONCLUSIONS: The existing limited efficacy and safety data suggest that valproic acid should not replace conventional therapy or be used as adjunct therapy for management of mild-to-moderate AWS.
Authors:
Elaine Lum; Sean K Gorman; Richard S Slavik
Related Documents :
12183663 - Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
22479293 - Melorheostosis and its treatment with intravenous zoledronic acid.
1906843 - Selective induction of metabolic activation programs in peritoneal macrophages by lipop...
Publication Detail:
Type:  Journal Article; Review     Date:  2006-02-28
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  40     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-03-07     Completed Date:  2006-04-26     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  441-8     Citation Subset:  IM    
Affiliation:
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alcohol Withdrawal Delirium / drug therapy*
Anticonvulsants / adverse effects,  therapeutic use*
Benzodiazepines / therapeutic use
Humans
Randomized Controlled Trials as Topic
Valproic Acid / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anticonvulsants; 12794-10-4/Benzodiazepines; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of hepatitis C in HIV-coinfected patients.
Next Document:  Dalbavancin: a new option for the treatment of gram-positive infections.